NIAID TETRAMER FACILITY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 美国国家过敏症和传染病研究所(NIAID)支持为研究界提供集中资源的试剂项目和资料库。这些设施通过以合理的价格向合格的研究人员提供可靠的有质量保证的材料、标本或实验动物来源来支持研究。NIAID四聚体设施于1998年在约翰·奥特曼博士的指导下在埃默里大学建立，作为基础、临床前和临床研究的质量控制四聚体试剂的集中来源，为科学界服务。NIAID艾滋病部门监督该设施，该设施由艾滋病研究和参考试剂计划承包，分包给McKesson BioServices和弗吉尼亚·梅森。 该机构已经向美国和国外非营利性组织的研究人员提供了包括人类、小鼠和非人类灵长类MHC等位基因的四聚体试剂，包括得到美国国立卫生研究院、食品和药物管理局、国防部、疾病控制和预防中心和美国私人非营利性基金会支持的研究人员，以及欧洲、澳大利亚、以色列和加拿大的研究人员；生产了适用于广泛T细胞研究的四聚体，包括艾滋病和其他传染病、癌症、器官移植、自身免疫、临床疫苗评估和T细胞和免疫反应的基础研究；并开发了四聚体使用的标准化方法，并评估了四聚体设计和生产方面的新进展，以确保该设施的试剂反映最先进的能力。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The National Institute of Allergy and Infectious Diseases (NIAID) supports reagent programs and repositories that provide centralized resources for the research community. These facilities support research by providing reliable sources of quality assured materials, specimens, or experimental animals at reasonable cost to qualified investigators. The NIAID Tetramer Facility, established at Emory University in 1998 under the direction of John Altman, Ph.D., serves the scientific community as a centralized source of quality-controlled tetramer reagents for basic, preclinical, and clinical research. The NIAID Division of AIDS oversees the Facility, which is contracted by the AIDS Research and Reference Reagent Program with subcontracts to McKesson BioServices and Virginia Mason. The Facility has provided tetramer reagents, comprising human, murine, and non-human primate MHC alleles to researchers at non-profit organizations both in the U.S. and abroad, including investigators supported by ten NIH Institutes, the Food and Drug Administration, the Department of Defense, the Centers for Disease Control and Prevention, and private non-profit U.S. foundations, as well as to researchers in Europe, Australia, Israel, and Canada; has produced tetramers applicable to a wide range of T cell studies, including research on AIDS and other infectious diseases, cancer, organ transplantation, autoimmunity, clinical vaccine evaluation, and basic studies on T cells and immune responses; and has developed standardized methodology for tetramer usage and evaluated new advances in tetramer design and production to assure that the Facility's reagents reflect state-of-the-art capabilities.